High-Efficiency Bohle Tablet Coater - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

High-Efficiency Bohle Tablet Coater


L.B. Bohle has developed the future of tablet coating, the high-efficiency Bohle Tablet Coater (BTC). The tablet coater reduces processing times up to 35 percent compared to conventional tablet coating systems, yielding significant cost savings and improved campaign efficiency while maintaining cGMP standards.

The BTC provides superior coating uniformity, producing considerably fewer rejects and using less coating material. L.B. Bohle’s patented air flow bed technology eliminates spray drying, thereby reducing waste while lengthening campaigns between cleaning. It also promotes uniform tablet coating with a high-quality, defect-free film coat.

The tablet coater’s elongated coating pan provides a larger tablet spraying surface accommodating up to 10 spray nozzles, which delivers more suspension solution and reduces overall coating time. The BTC’s integrated mixing baffles are double-helix shaped to ensure thorough tablet mixing with gentle handling. The baffle design provides 100-percent tablet discharge, increasing campaign efficiency.

The BTC is ergonomically designed for efficient material handling and is capable of Wash-in-Place (WIP) cleaning. The BTC spray arm and nozzles are mounted on the front door assembly, simplifying inspection and maintenance.

 

The L.B. Bohle Coating products:

  • Bohle Tablet Coater BTC
  • Bohle Film Coater BFC TriPan
  • Bohle Film Coater BFC

Contact:
Tobias Borgers
Head of Marketing
Phone: +49 25 24 - 93 23 0
Fax: +49 25 24 - 93 23 399
Email: t.borgers@lbbohle.de
Web: www.lbbohle.com

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
32%
Breakthrough designations
8%
Protecting the supply chain
40%
Expedited reviews of drug submissions
8%
More stakeholder involvement
12%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests

Click here